tradingkey.logo
搜尋

Charles River Laboratories International Inc

CRL
添加自選
234.300USD
-0.500-0.21%
收盤 07-29 16:00美東報價延遲15分鐘
11.29B總市值
虧損本益比TTM

Charles River Laboratories International Inc

234.300
-0.500-0.21%

關於 Charles River Laboratories International Inc 公司

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Charles River Laboratories International Inc簡介

公司代碼CRL
公司名稱Charles River Laboratories International Inc
上市日期Jun 23, 2000
CEOFoster (James C)
員工數量18600
證券類型Ordinary Share
年結日Jun 23
公司地址251 Ballardvale St
城市WILMINGTON
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編01887
電話17812226000
網址https://www.criver.com/
公司代碼CRL
上市日期Jun 23, 2000
CEOFoster (James C)

Charles River Laboratories International Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
58.79K
-5.76%
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
26.98K
-920.54%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
20.94K
+19.00%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
14.72K
+26.15%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Corporate Executive Vice President - Discovery and Safety Assessment Management
10.72K
-14.26%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
6.35K
+22.65%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
4.56K
+43.24%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
3.85K
+37.34%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
2.38K
+60.32%
Mr. Paul W. Graves
Mr. Paul W. Graves
Independent Director
Independent Director
2.38K
+60.32%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
58.79K
-5.76%
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
26.98K
-920.54%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
20.94K
+19.00%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
14.72K
+26.15%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Corporate Executive Vice President - Discovery and Safety Assessment Management
10.72K
-14.26%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
6.35K
+22.65%

常見問題

Charles River Laboratories International Inc的前五大股東是誰?

Charles River Laboratories International Inc的前五大股東如下:Ms. Birgit Girshick

有多少機構持有Charles River Laboratories International Inc(CRL)的股份?

截至2026Q1,共有1429家機構持有Charles River Laboratories International Inc的股份,合計持有的股份價值約為56.13M,占公司總股份的116.51% 。與2025Q4相比,機構持股有所增加,增幅為-7963916.00。

哪個業務部門對Charles River Laboratories International Inc的收入貢獻最大?

在2026Q1,DSA業務部門對Charles River Laboratories International Inc的收入貢獻最大,創收2.40B,占總收入的59.84% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有